Continuous Glucose Monitoring — Coming of Age

Abstract

Advances in glucose-monitoring technology have been an important driver for improvements in the treatment of type 1 diabetes. The introduction of fingerstick capillary blood glucose monitoring in the 1970s set the stage for the era of intensive insulin therapy, leading to a substantial reduction in the risk of long-term complications from diabetes. The tradeoff with intensive diabetes management is a marked increase in episodes of severe hypoglycemia. Real-time continuous glucose monitoring, a technology first approved by the Food and Drug Administration in 2005, helps to address this therapeutic challenge.In this issue of the Journal, Bergenstal et al.1 report the . . .